According to a Wall Street Journal report, Johnson & Johnson and the U.S. Justice Department are close to settling a lengthy investigation into allegations that the company used illegal tactics in marketing its antipsychotic drug Risperdal.
The report cites unnamed sources who said the settlement would be one of the highest ever in a drug marketing case.
Federal law says drug makers can market medicines only for uses approved by the U.S. ...
continue reading...
In a recent article, The Motley Fool writer Catherine Baab-Muguira addresses a number of recent management errors and product recalls at Johnson & Johnson.
She writes that they’ve “had investors scratching their heads and asking: Is Johnson & Johnson broken?”
The Department of Justice filed a civil False Claims Act against Johnson & Johnson in 2010, alleging that the company had illegally paid kickbacks to nursing-home pharmaceutical supplier Omnicare to induce Omnicare ...
continue reading...Despite Minnesota-based Medtronic’s announcement that the federal government has closed its investigation into the marketing of a bone growth agent called Infuse, the company’s legal troubles are not over.
According to an article in the Pioneer Press, a number of other legal inquiries are ongoing into claims that the company promoted Infuse for off-label uses, despite reports that such uses were causing serious and permanent injuries to patients.
They include a subpoena the California Attorney General’s office issued in 2011, and several ...
continue reading...Johnson & Johnson officials hope the $19.7 billion acquisition of Synthes, which makes surgical trauma equipment and orthopedic implants, will give the company a dominant position in the orthopedic surgery market.
According to a Bloomberg report, Johnson & Johnson’s prescription drugs and consumer health segments have both suffered revenue losses in recent years following a series of recalls.
Johnson & Johnson has launched about two dozen recalls of nonprescription drugs and at ...
continue reading...
Bloomberg reports that Johnson & Johnson has agreed to pay as much as $2.2 billion to settle federal government investigations into claims that the company illegally marketed antipsychotic drug Risperdal and other medications.
The report quotes unnamed sources as saying the settlement will include a misdemeanor plea and a criminal penalty of as much as $600 million.
But that wouldn’t be the end of Johnson & Johnson’s legal troubles. The company is ...
continue reading...The U.S. Food and Drug Administration has ordered a labeling change for the epilepsy medication ethosuximide, sold under the brand name Zarontin, reflecting the agency’s determination that it can cause serious skin conditions including the potentially fatal Stevens-Johnson syndrome.
According to the Mayo Clinic, Stevens-Johnson syndrome is a rare, serious disorder in which the skin and mucous membranes react severely to a medication or infection.
The Mayo Clinic describes Stevens-Johnson syndrome as a medical emergency that usually requires hospitalization. It often begins ...
continue reading...
